1
|
Melekoglu E, Bayram E, Secmeler S, Mete B, Sahin B. Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT. Nutrients 2023; 15:4156. [PMID: 37836440 PMCID: PMC10574228 DOI: 10.3390/nu15194156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Revised: 09/15/2023] [Accepted: 09/20/2023] [Indexed: 10/15/2023] Open
Abstract
The adverse effects of chemotherapy are more apparent in elderly patients and lead to worse prognosis and mortality. Identifying immunonutritional risk factors is of great importance in terms of treatment effectiveness, prognosis, and mortality in geriatric oncology. The modified Glasgow prognostic score (mGPS) is an immunonutritional index based on serum CRP and albumin levels. In this study, we aimed to investigate the role of mGPS in predicting prognosis and survival in elderly patients with gastric cancer receiving perioperative FLOT treatment. We retrospectively enrolled 71 patients aged over 65 years and grouped them according to their pretreatment mGPS score. Kaplan-Meier and Cox regression analysis showed overall survival was significantly worse in the mGPS 1 and mGPS 2 groups than in the mGPS 0 group (p = 0.005 and p < 0.001, respectively). Compared to the mGPS 0 group, the mGPS 1 group had a 6.25 times greater risk of death (95% CI: 1.61-24.28, p = 0.008), and the mGPS 2 group had a 6.59 times greater risk of death (95% CI: 2.08-20.85, p = 0.001). High BMI was identified as a significant risk factor for being in the mGPS 2 group (OR: 1.20, 95% CI: 1.018-1.425, p = 0.030). In conclusion, elevated pretreatment mGPS was associated with poor overall survival in elderly patients with gastric cancer treated with perioperative FLOT therapy. As such, pretreatment mGPS can be a simple and useful tool to predict mortality in this specific patient group.
Collapse
Affiliation(s)
- Ebru Melekoglu
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Cukurova University, Adana 01250, Turkey
| | - Ertugrul Bayram
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Turkey; (E.B.); (B.S.)
| | - Saban Secmeler
- Department of Medical Oncology, Bahcelievler Medicalpark Hospital, Altinbas University, Istanbul 34180, Turkey;
| | - Burak Mete
- Department of Public Health, Faculty of Medicine, Cukurova University, Adana 01250, Turkey;
| | - Berksoy Sahin
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Turkey; (E.B.); (B.S.)
| |
Collapse
|
2
|
Bayram E, Sahin B. Awareness and obscurity: demystifying genomic profiling in real-world practice for the members of the Turkish Society of Medical Oncology (TSMO). Eur Rev Med Pharmacol Sci 2023; 27:4145-4152. [PMID: 37203840 DOI: 10.26355/eurrev_202305_32323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
OBJECTIVE Molecular testing in oncology practice is increasingly being used to offer more relevant therapies to cancer patients. Our study aims to determine the real-world impact of routine incorporation of molecular testing among the Turkish Oncology community across all types of cancer and identify gaps for the first time. SUBJECTS AND METHODS This research was conducted in Turkey among medical oncologists from different backgrounds. The survey attendance was entirely voluntary. A questionnaire with twelve items (multiple choice +/- closed-ended) was utilized in this study to assess the effect of molecular tests in real clinical situations. RESULTS 102 oncologists with various levels of experience participated in this study. Most of the respondents (97%) reported successful implementation of molecular testing. About 10% of the participating oncologists said they preferred genetic tests at the early stages of cancer, compared to the majority who preferred genetic tests at the terminal stage. Molecular tests are often performed in separate locations and 47% of the oncologists were using a targeted panel specific to the type of malignancy. CONCLUSIONS Several informational difficulties must be resolved in order to have early personalized therapy as the standard treatment. We need accessible, comprehensive, and regularly updated databases to compare genetic profiling and its therapeutic implications. We also need to continue educating patients and physicians.
Collapse
Affiliation(s)
- E Bayram
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
| | | |
Collapse
|
3
|
Kutluk T, Sahin B, Kirazli M, Ahmed F, Aydin S, Yesil Çinkir H, Sezgin G, Bayram I, Ebinç S, Isikdogan A, Sasmaz I, Okan V, Ilhan G, Ören AC, Akbayram S, Harputluoglu H, Ural C, Ayyildiz O, Aktas G, Uçar MA, Güvenç B, Köse D, Acipayam C, Güncan S, Erçolak V, Berber I, Akdeniz A, Akyay A, Üzel VH, Söker M, Sengelen M, Yalçin S, Sullivan R. Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey. JAMA Netw Open 2023; 6:e2312903. [PMID: 37219908 DOI: 10.1001/jamanetworkopen.2023.12903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/24/2023] Open
Abstract
Importance Cancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are needed. Objective To explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees. Design, Setting, and Participants This was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022. Main Outcomes and Measures Demographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment. Results A total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 [13.8%]), leukemia and multiple myeloma (147 [13.2%]), and lymphoma (141 [12.7%]) were common among adults, and leukemias (180 [42.8%]), lymphomas (66 [15.7%]), and central nervous system neoplasms (40 [9.5%]) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children. Conclusions and Relevance Despite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.
Collapse
Affiliation(s)
- Tezer Kutluk
- Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey
| | - Berksoy Sahin
- Department of Medical Oncology, Çukurova University, Adana, Turkey
| | - Meral Kirazli
- Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey
| | - Fahad Ahmed
- Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey
- Now with Department of Public Health, Yıldırım Beyazıt University, Ankara, Turkey
| | - Sinem Aydin
- Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey
| | | | - Gülay Sezgin
- Department of Pediatric Hematology-Oncology, Çukurova University, Adana, Turkey
| | - Ibrahim Bayram
- Department of Pediatric Hematology-Oncology, Çukurova University, Adana, Turkey
| | - Senar Ebinç
- Department of Medical Oncology, Dicle University, Diyarbakır, Turkey
| | | | - Ilgen Sasmaz
- Department of Pediatric Hematology, Çukurova University, Adana, Turkey
| | - Vahap Okan
- Department of Hematology, Gaziantep University, Gaziantep, Turkey
| | - Gül Ilhan
- Department of Hematology, Mustafa Kemal University, Hatay, Turkey
| | - Ayse Ceyda Ören
- Department of Pediatric Hematology-Oncology, Gaziantep University, Gaziantep, Turkey
| | - Sinan Akbayram
- Department of Pediatric Hematology-Oncology, Gaziantep University, Gaziantep, Turkey
| | | | - Cihan Ural
- Department of Hematology, Dicle University, Diyarbakır, Turkey
| | - Orhan Ayyildiz
- Department of Hematology, Dicle University, Diyarbakır, Turkey
| | - Gökmen Aktas
- Department of Medical Oncology, Sütçü İmam University, Kahramanmaraş, Turkey
- Now at Medicalpoint Gaziantep Hospital, Gaziantep, Turkey
| | - Mehmet Ali Uçar
- Department of Hematology, Çukurova University, Adana, Turkey
| | - Birol Güvenç
- Department of Hematology, Çukurova University, Adana, Turkey
| | - Dogan Köse
- Department of Pediatric Oncology, Harran University, Şanlıurfa, Turkey
- Now at Emsey Hospital, İstanbul Turkey
| | - Can Acipayam
- Department of Pediatric Hematology-Oncology, Sütçü İmam University, Kahramanmaraş, Turkey
| | - Sabri Güncan
- Department of Medical Oncology, Mersin University, Mersin, Turkey
| | - Vehbi Erçolak
- Department of Medical Oncology, Mersin University, Mersin, Turkey
| | - Ilhami Berber
- Department of Hematology, İnönü University, Malatya, Turkey
| | - Aydan Akdeniz
- Department of Hematology, Mersin University, Mersin, Turkey
| | - Arzu Akyay
- Department of Pediatric Hematology-Oncology, İnönü University, Malatya, Turkey
| | - Veysiye Hülya Üzel
- Department of Pediatric Hematology-Oncology, Dicle University, Diyarbakır, Turkey
| | - Murat Söker
- Department of Pediatric Hematology-Oncology, Dicle University, Diyarbakır, Turkey
| | - Meltem Sengelen
- Department of Public Health, Hacettepe University, Ankara, Turkey
| | - Suayib Yalçin
- Department of Medical Oncology, Hacettepe University, Ankara, Turkey
| | - Richard Sullivan
- King's College London, Institute of Cancer Policy, Conflict & Health Research Group, London, United Kingdom
| |
Collapse
|
4
|
Bayram E, Sahin B, Koseci T, Bisgin A. 927P Awareness & obscurity: Demystifying genomic profiling in real-world practice for the members of Turkish Society of Medical Oncology (TSMO). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin D, Weitz JI. OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIn the ORAL Surveillance study of patients (pts) aged ≥50 yrs with moderate to severe rheumatoid arthritis (RA) and ≥1 additional cardiovascular risk factor (NCT02092467), the incidence of pulmonary embolism was higher with tofacitinib than with tumour necrosis factor inhibitors (TNFi).1ObjectivesTo explore whether biomarkers explained the associations of tofacitinib vs TNFi with venous thromboembolism (VTE) in ORAL Surveillance.MethodsORAL Surveillance was a prospective, open-label, event-driven, noninferiority, post-authorisation safety study. Pts were randomised 1:1:1 to receive tofacitinib 5 or 10 mg twice daily or a TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg once weekly). For this exploratory post hoc analysis, 294 soluble, proteomic, genetic and antibody biomarkers were assessed (of which 79 have a known role in inflammation, coagulation, vascular biology and/or Janus kinase signalling). Biomarkers were quantified in serum collected at baseline (BL) and Month (M)12 in VTE cases and 4:1 matched controls. D-dimer was analysed with a larger control group (all eligible pts without VTE) and final adjudicated data from BL, M12 and study end.ResultsOf the 4362 randomised and treated pts, D-dimer was quantified in 3732 pts (54 with VTE; 3678 without) and the remaining biomarkers were analysed in 285 pts (57 VTE cases; 228 matched controls). BL characteristics were generally similar in those with or without VTE and between treatment groups. At BL, D-dimer levels were ≥2×upper limit of normal for ~50% of controls and 67% of VTE cases. Mean D-dimer levels decreased from BL to M12 in controls across treatment groups (Figure 1). Key findings from the biomarker analyses are shown in the Table 1. No biomarker showed a clear mechanistic association with the increased risk of VTE for tofacitinib vs TNFi, or demonstrated adequate performance for prognostic use in pts with RA.Table 1.Summary of results from biomarker analysesBiomarkerKey resultsTier 1C-reactive protein•No association with VTE in any treatment arm at BL or M12D-dimer Thrombopoietin•Higher M12 levels were prospectively associated with greater risk of subsequent VTE with tofacitinib 10 mg BID ◦ For D-dimer, the same effect was observed with tofacitinib 5 mg BID •Treatment specificity of effects could not be establishedTier 2Factor VIII Thrombin–antithrombin complex Tissue factor pathway inhibitor Plasminogen activator inhibitor-1 Protein C Antithrombin Apolipoprotein C-III Leptin•No clinically meaningful differences across treatment armsTiers 3 & 4Exploratory proteomic assays (276 markers from multiplex panels)•Two biomarkers with no known relationship to VTE (angiogenin and TNFSF13B) showed significant associations with pulmonary embolism in the tofacitinib 10 mg BID arm ◦ Treatment specificity of effects could not be established for either analyteGenetic biomarkersFactor V Leiden R506Q, prothrombin G20210A and JAK2 V617F mutations•Factor V Leiden and prothrombin risk alleles, individually or combined, were associated with increased incidence of VTE but did not explain excess events with tofacitinib •No VTE cases or matched controls had the JAK2 mutationAntibody biomarkersACA IgG and IgM, anti-β2GP1 IgG and IgM•No statistical differences were observed between treatment arms or between VTE cases and matched controlsACA, anticardiolipin antibody; β2GP1, beta-2-glycoprotein 1; IgG, immunoglobulin G; IgM, immunoglobulin M; JAK2, Janus kinase 2; TNFSF13B, tumour necrosis factor ligand superfamily member 13BConclusionThis post hoc exploratory analysis did not identify biomarkers at BL or M12 that explain the increased VTE risk for tofacitinib vs TNFi. Notably, ORAL Surveillance was neither designed nor powered to compare the risk of VTE across treatments or to identify biomarkers with a mechanistic relationship to VTE. Individual VTE risk should be considered when making decisions about initiation or maintenance of tofacitinib treatment.References[1]Ytterberg et al. N Engl J Med 2022; 386: 316-326.AcknowledgementsStudy sponsored by Pfizer Inc. Medical writing support was provided by Julia King, CMC Connect, and funded by Pfizer Inc.Disclosure of InterestsZoltán Szekanecz Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Paid instructor for: AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Grant/research support from: Pfizer Inc, Christina Charles-Schoeman Consultant of: AbbVie, Gilead Sciences, Pfizer Inc and Sanofi-Regeneron, Grant/research support from: AbbVie, Bristol-Myers Squibb and Pfizer Inc, Ivana Vranic Shareholder of: Pfizer Inc, Employee of: Pfizer Ltd, Burak Sahin Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Sara A Paciga Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Zhenyu Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Craig Hyde Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, David Martin Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jeffrey I Weitz Speakers bureau: Anthos, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Novartis, Pfizer Inc, PhaseBio, Portola and Servier Pharmaceuticals, Grant/research support from: Bayer AG and Boehringer Ingelheim
Collapse
|
6
|
Baspinar SN, Durucan I, Yuzbasioglu MB, Yenigun S, Ayla AY, Alkan A, Ayalti T, Demirkol F, Sahin B, Alizade S, Ozdogan H, Ugurlu S. AB1323 THE MYSTERY OF FAMILIAL MEDITERRANEAN FEVER: IS THERE ANY FACTOR TRIGGERING THE ATTACKS? Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundFamilial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent episodes of fever and serositis. Although it is known that the attack frequency differs among patients carrying different mutant genotypes [1], whether physical and environmental factors play a role in triggering attacks or whether they have an influence on timing of attacks remains to be elucidated.ObjectivesWe aimed to identify different conditions causing flare-ups in FMF course and to investigate if there is a significant difference between patients carrying distinct mutations, regarding the distribution of the factors mentioned.MethodsTwo hundred patients were randomly selected among individuals who were routinely followed-up with FMF diagnosis in our centre. Individuals carrying only a variant of unknown significance or polymorphism such as R202Q, according to Infevers database, were excluded in order to gather a cohort consisting of patients with definite FMF. An inquiry was made based upon triggering factors determined by the patients themselves. The patients were classified into subgroups by their sex and mutation genotype. Since M694V variant is responsible for pronounced FMF course [2], we sorted the patients according to their status for M694V mutant allele. Group A included patients carrying M694V homozygously. Group B included patients carrying at least one M694V mutant allele whereas Group C consisted of patients who were non-M694V carriers. Chi-square test was performed to assess distribution of the trigger factors in terms of establishing its significance.ResultsDetailed distribution of trigger factors is shown in Table 1. 144 out of 200 patients described a culprit condition. Patients usually stated more than one factor, however some patients reported only one. The most-reported trigger factors by the cohort are summarized as following: 76 emotional stress (38%), 60 menstruation (30%), 40 cold exposure (20%), 34 fatigue (17%), 13 seasonal changes (6.5%). The distribution of trigger factors between Group A, B, and C were non-significant (p=0.88).Table 1.The distribution of triggering factors in subgroups.GroupTotal(%)Reported trigger factor (%)Mens- truation(%)Emotionalstress(%)Cold exposure(%)Fatigue(%)Seasonalchanges(%)Others(%)Female12397 (78.8)60 (48.8)47 (38.2)24 (19.5)19 (15.4)7 (5.7)6 (4.9)Male7747 (61)-29 (37.7)16 (20.8)15 (19.5)6 (7.8)7 (9.1)Group A6144 (72.1)14 (23)24 (39.3)13 (21.3)12 (19.7)4 (6.6)6 (9.8)Group B165120 (72.7)49 (29.7)66 (40)34 (20.6)29 (17.6)13 (7.9)11 (6.6)Group C3524 (68.6)11 (31.4)10 (28.6)6 (17.1)5 (14.3)01 (2.8)Group A: M694V homozygous patients, Group B: patients with at least one M694V allele, Group C: non-M694V carriersConclusionWe concluded that trigger factors did not vary between distinct mutant genotypes. Although emotional stress is the most reported trigger factor by the participants, one should bear in mind that emotional stress influences most chronic diseases negatively. We also observed that menstruation overtly triggers an FMF attack. Additionally, cold exposure should be considered as a notable trigger factor. It is still unclear what triggers an FMF attack in 28% of the patients, remains a mystery.References[1]Grossman C, Kassel Y, Livneh A, Ben-Zvi I. Familial Mediterranean fever (FMF) phenotype in patients homozygous to the MEFV M694V mutation. Eur J Med Genet. 2019 Jun;62(6):103532. doi: 10.1016/j.ejmg.2018.08.013.[2]Egeli BH, Ugurlu S. Familial Mediterranean Fever: Clinical State Of The Art. QJM. 2020 Oct 20:hcaa291. doi: 10.1093/qjmed/hcaa291.Disclosure of InterestsNone declared
Collapse
|
7
|
Zheng B, Keen K, Fritzler M, Ryerson C, Wilcox P, Whalen B, Sahin B, Hou H, Latham P, Zhang MF, Yao I, Dunne J. POS0869 CYTOKINES IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundImmune pathways have been implicated in both systemic sclerosis (SSc)-related interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Determination of blood cytokine differences in these two disorders need to be elucidated to better understand potential biological processes and common pathogenic pathways.ObjectivesThis study compared 87 circulating cytokine levels amongst healthy controls and both SSc-ILD and IPF. There was also exploration of the association between cytokine levels and disease progression based on the annualized rate of decline of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO).MethodsLevels of 87 plasma cytokines were measured using commercial panels for consecutive SSc-ILD, IPF, and healthy individuals recruited at a Canadian tertiary-care center. Pulmonary function tests were performed as clinically indicated every 3-12 months. Cytokine levels are compared using the Wilcoxon rank sum test for two samples pairwise. The association between differentially expressed cytokines with both percent predicted annualized FVC and DLCO change was assessed within each disease group using multiple linear models adjusted for age, sex, baseline FVC, and immunosuppressive or anti-fibrotic treatment at sampling. Correction for multiplicity of testing was by Holm’s method.ResultsThere were 19 healthy controls, 40 SSc-ILD, and 17 IPF participants with clinical features shown in Table 1. Eotaxin-1 and interleukin 6 (IL-6) were significantly elevated in both SSc-ILD and IPF compared to healthy controls (Figure 1). SSc-ILD had significantly lower soluble epidermal growth factor receptor (sEGFR) and higher levels of both soluble tumor necrosis factor receptor type II (sTNFRII) and soluble vascular endothelial growth factor receptor-1 (sVEGFR1) compared to healthy controls. IPF cases were distinguished from healthy controls by significantly higher monocyte chemoattractant protein-1 (MCP-1) and monokine induced by gamma interferon (MIG, also known as CXCL9) levels. No significant association was found for any of the cytokines with ILD progression based on annualized rates of either FVC or DLCO change.Table 1.Baseline patient characteristics stratified by disease groupsHealthy control(n = 19)SSc-ILD(n = 40)IPF(n = 17)Age, year51 ± 1956 ± 1273 ± 7Male, count (%)6 (32)12 (30)12 (71)Disease duration, yearNA6.41 (7.81)1.76 (2.14)Ever smoker, count (%)2 (11)19 (48)14 (82)•4 (82)oker0.4 [0, 1]11 [4, 29]19 [11, 35]Treatment presence, count (%)NA16 (40)7 (41)Baseline FVC %NA80 ± 2285 ± 21Baseline DLCO %NA51 ± 1749 ± 11Annualized FVC % changeNA-1.7 ± 8.2-6.2 ± 13.6Annualized DLCO % changeNA-0.5 ± 6.2-7.8 ± 18.6The number (%), mean ± standard deviation, and median [interquartile range] are shown. Disease duration is defined as time of ILD first seen on HRCT in IPF and time from first non-Raynaud’s phenomenon in SSc-ILD. Treatment includes presence of ILD therapies: nintedanib, pirfenidone, mycophenolate mofetil, azathioprine, rituximab. FVC = forced vital capacity, DLCO = diffusing capacity for carbon monoxideFigure 1.Notched box plots of cytokine differences between disease groups. All cytokine levels are shown on a log scale. Overlap of notches indicates lack of a statistically significant difference in medians in a pairwise comparison. P-values are for SSc-ILD or IPF compared to healthy controls using Wilcoxon rank sum two-sample test corrected for multiple testing using Holms method.ConclusionDifferences in seven circulating cytokines between healthy controls with both SSc-ILD and IPF show evidence of systemic cytokine activation. All seven cytokines have a role in immune cell extravasation and pro-fibrotic signaling, which provides further evidence of immune pathways involved in pulmonary fibrosis. Further studies will be pursued of longitudinal change of these biomarkers for halting or slowing disease progression and improving response to treatment.Disclosure of InterestsBoyang Zheng: None declared, Kevin Keen Grant/research support from: Merck Canada Inc, Marvin Fritzler Shareholder of: Abbott Laboratories; Roche Holdings; Abcellera; Moderna, Speakers bureau: For diagnostic company: Werfen, Consultant of: For diagnostic company: Werfen; Aesku, Employee of: Medical Director of Mitogen Diagnostics, Christopher Ryerson Speakers bureau: Boehringer Ingelheim, Hoffmann-La Roche, Consultant of: Boehringer Ingelheim, Hoffmann-La Roche, Veracyte, Astra Zeneca, Grant/research support from: Boehringer Ingelheim, Hoffmann-La Roche, Pearce Wilcox Speakers bureau: Vertex, Valeo, Boehringer, Beth Whalen: None declared, Basak Sahin: None declared, Haiyan Hou Employee of: Mitogen Diagnostics, Penny Latham Employee of: Eve technologies, Mei Feng Zhang Employee of: Mitogen diagnostics, Iris Yao: None declared, James Dunne: None declared
Collapse
|
8
|
Aybers MN, Sahin B. Nuclear power costs in the build, operate, transfer approach / Die Kosten der Kernenergie beim BOT-Vertragsmodell. KERNTECHNIK 2021. [DOI: 10.1515/kern-1990-550123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Kocaturk M, Inan OE, Tvarijonaviciute A, Sahin B, Baykal AT, Cansev M, Ceron JJ, Yilmaz Z, Ulus IH. Nasal secretory protein changes following intravenous choline administration in calves with experimentally induced endotoxaemia. Vet Immunol Immunopathol 2021; 233:110197. [PMID: 33550189 DOI: 10.1016/j.vetimm.2021.110197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 01/19/2021] [Accepted: 01/23/2021] [Indexed: 10/22/2022]
Abstract
Nasal secretory fluid proteomes (NSPs) can provide valuable information about the physiopathology and prognosis of respiratory tract diseases. This study aimed to determine changes in NSP by using proteomics in calves treated with lipopolysaccharide (LPS) or LPS + choline. Healthy calves (n = 10) were treated with LPS (2 μg/kg/iv). Five minutes after LPS injection, the calves received a second iv injection with saline (n = 5, LPS + saline group) or saline containing 1 mg/kg choline (n = 5, LPS + choline group). Nasal secretions were collected before (baseline), at 1 h and 24 h after the treatments and analysed using label-free liquid chromatography-tandem mass spectrometry (LCMS/MS). Differentially expressed proteins (>1.2-fold-change) were identified at the different time points in each group. A total of 52 proteins were up- and 46 were downregulated at 1 h and 24 h in the LPS + saline group. The upregulated proteins that showed the highest changes after LPS administration were small ubiquitin-related modifier-3 (SUMO3) and glutathione peroxidase-1 (GPX1), whereas the most downregulated protein was E3 ubiquitin-protein ligase (TRIM17). Treatment with choline reduced the number of upregulated (32 proteins) and downregulated proteins (33 proteins) in the NSPs induced by LPS. It can be concluded that the proteome composition of nasal fluid in calves changes after LPS, reflecting different pathways, such as the activation of the immunological response, oxidative stress, ubiquitin pathway, and SUMOylation. Choline treatment alters the NSP response to LPS.
Collapse
Affiliation(s)
- M Kocaturk
- Department of Internal Medicine, Faculty of Veterinary Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
| | - O Eralp Inan
- Medical and Surgical Experimental Animal Practice and Research Center, Eskisehir Osmangazi University, 26480, Eskisehir, Turkey.
| | - A Tvarijonaviciute
- Interdisciplinary Laboratory of Clinical Analysis, Interlab-UMU, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia 30100, Spain.
| | - B Sahin
- Acibadem Labmed Research and Development Center, Istanbul, Turkey.
| | - A T Baykal
- Department of Medical Biochemistry, Acibadem University School of Medicine, Istanbul, Turkey.
| | - M Cansev
- Department of Pharmacology, Bursa Uludag University School of Medicine, Bursa, Turkey.
| | - J J Ceron
- Interdisciplinary Laboratory of Clinical Analysis, Interlab-UMU, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia 30100, Spain.
| | - Z Yilmaz
- Department of Internal Medicine, Faculty of Veterinary Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
| | - I H Ulus
- Department of Pharmacology, Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
| |
Collapse
|
10
|
Ongun S, Esen C, Ozer S, Yildirim O, Duran B, Kazaz I, Sahin B, Hasirci E, Deliktas H, Sah C, Kizilkan Y, Cinar O. P-02-20 The Relationship Between Premature Ejaculation and the Timing of the Pre-Adult Circumcision. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2020.04.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Sahin B, Kızılkan Y, Yıldırım Ö, Şah C, Kazaz İ, Cihan A, Duran B, Ongün Ş, Üre İ, Deliktaş H, Çınar Ö, Gül Ü, Güdeloğlu A, Turunç T. P-02-58 Hypogonadism Prevalence Among Men WHO Admitted to Urology Outpatient Clinic in Turkey: A Multicentric Study. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2020.04.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Saritas AG, Atar C, Gul MO, Teke Z, Ulku A, Sahin B. Bilateral breast lesions mimicking metastases of hepatocellular carcinoma in a male patient. Ann Ital Chir 2020; 9:S2239253X2003279X. [PMID: 32554904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Hepatocellular carcinoma metastases to the breast have been reported only rarely. A 63-year-old male patient with metastatic hepatocellular carcinoma presented with a lump in his left breast. On physical examination, there was a hard, well-circumscribed, and partially mobile mass of 2 cm in diameter in the lower middle quadrant of the left breast. Breast ultrasound revealed a hypoechoic solid lesion of 1.8 cm × 1.9 cm in diameter in the lower middle quadrant of the left breast. F-18 FDG PET/CT imaging revealed bilateral subcutaneous nodular lesions of anterior chest wall that were adjacent but not invasive to the glandular tissues of the breasts, with high SUVmax values. Tru-cut biopsy result of the mass in the left breast region was reported as hepatocellular carcinoma metastasis. Positive immunohistochemical staining for Hep Par 1 and glypican-3 were detected. While the patient was on sorafenib therapy, he died 6 months later. Hepatocellular carcinoma is a common malignancy for which chronic hepatitis B infection has been defined as the most common etiologic factor. The most frequent metastatic sites are the lung, bone, lymphatics, and brain, respectively, and metastases to the breast have been reported extremely rarely. Breast metastasis from non-mammary malignant neoplasm is rare, accounting for approximately 2% of breast tumors. Metastasis to the breast from an extramam mary neoplasm usually indicates disseminated metastatic disease and a poor prognosis. It should be borne in mind that a mass lesion detected in the breast region by physical examination and imaging methods may be a hepatocellular carcinoma metastasis in male or female patients with hepatocellular carcinoma. KEY WORDS: Breast, Hepatocellular carcinoma, Metastasis.
Collapse
|
13
|
Yalcin S, Gumus M, Oksuzoglu B, Ozdemir F, Evrensel T, Sarioglu AA, Sahin B, Mandel NM, Goker E. Nutritional Aspect of Cancer Care in Medical Oncology Patients. Clin Ther 2019; 41:2382-2396. [PMID: 31699437 DOI: 10.1016/j.clinthera.2019.09.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 09/04/2019] [Accepted: 09/05/2019] [Indexed: 01/07/2023]
Abstract
PURPOSE Awareness of advances in the nutritional aspects of cancer care and translation of this information into clinical practice are important for oncology practitioners to effectively couple oncologic and nutritional approaches throughout the cancer journey. The goal of this consensus statement by a panel of medical oncologists was to provide practical and implementable guidance addressing nutritional aspects of cancer care from the perspective of the medical oncologist. METHODS A panel of medical oncologists agreed on a series of statements supported by scientific evidence and expert clinical opinion. FINDINGS Participating experts emphasized that both poor nutritional intake and metabolic alterations underlie cancer-related malnutrition. The use of liquid and high energy-dense oral nutritional supplements may enable better patient compliance, whereas higher efficacy is more likely with the use of pharmaconutrient-enriched oral nutritional supplements in terms of improved weight, lean body mass, functional status, and quality of life, as well as better tolerance to antineoplastic treatment. A multimodal approach is currently believed to be the best option to counteract the catabolism leading to cancer-related malnutrition; this treatment is scheduled in parallel with anticancer therapies and includes nutritional interventions, multitarget drug therapies, and exercise and rehabilitation programs. Participating experts emphasized the role of the oncologist as a reference professional figure in the coordination of nutritional care for patients with cancer within the context of complex and different clinical scenarios, particularly for permissive-adjunctive nutritional support. IMPLICATIONS This review article provides practical guidance addressing major nutritional aspects of cancer care from the medical oncologist's perspective. Thus, this document is expected to assist oncology practitioners in terms of awareness of advances in the nutritional aspects of cancer care and translation of this information into their clinical practice to effectively couple oncologic and nutritional approaches as part of the continuum of care for patients with cancer.
Collapse
Affiliation(s)
- Suayib Yalcin
- Hacettepe University Institute of Cancer, Ankara, Turkey.
| | - Mahmut Gumus
- Medeniyet University Faculty of Medicine, Istanbul, Turkey
| | - Berna Oksuzoglu
- Health Sciences University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Feyyaz Ozdemir
- Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
| | | | | | - Berksoy Sahin
- Çukurova University Faculty of Medicine, Adana, Turkey
| | | | - Erdem Goker
- Ege University Faculty of Medicine, Izmir, Turkey
| | | |
Collapse
|
14
|
Mustafayev T, Sahin B, Gungor G, Aydin G, Serbez I, Teymur B, Gur G, Arabaci G, Atalar B, Yapici B, Abacioglu U, Agaoglu F, Sengoz M, Ozyar E. Time Analysis in Magnetic Resonance Image-Guided Radiotherapy Workflow. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Etik DO, Parlak E, Oguz D, Oztas E, Kacar S, Onder FO, Sasmaz N, Sahin B. On demand pancreatic stenting in chronic pancreatitis might provide good palliation of pain. Acta Gastroenterol Belg 2019; 82:401-406. [PMID: 31566328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
BACKGROUND AND AIM Chronic pancreatitis (CP)-related pain is a considerable problem in gastroenterology practice that frequently requires several endoscopic interventions. We aimed to investigate the efficacy of pancreatic duct stenting performed on demand, instead of at defined intervals, for the management of the CP-related pain. METHODS This study is a retrospective evaluation of thirteen years of data. Sixty-seven patients with CP who suffered from intractable pain were enrolled in the study. Pancreatic stenting was performed mainly with single stents according to the diameter of the pancreatic duct and width of the stricture or, less frequently, with multiple stents aiming to achieve stricture resolution. The subsequent endoscopic session was scheduled based on the patient's symptoms. RESULTS Overall, 65 of 67 patients underwent successful pancreatic cannulation (technical success rate 97%). Fifty-seven patients with a pancreatic stenting history were still undergoing follow-up. Of these patients, 26 patients still had pancreatic ductal stents; however, the stents were removed from 31 patients. Only 8 patients (25%) required further endoscopic or surgical intervention because of the re-emergence of pain after a median stent-free period of 17 months (3-127 months). One patient with a biliary stricture and one patient with a pancreatic mass underwent surgery. Pancreatic stents remained for a median length of 14 months (3-84 months). During the follow-up period, 55 of 65 patients became pain-free or had partial pain relief (clinical success rate 84%). CONCLUSIONS On demand replacement of pancreatic stent is feasible in patients with CP and it might provide a good palliation of CP-related pain.
Collapse
Affiliation(s)
- D O Etik
- Department of Gastroenterology, Baskent University School of Medicine, Ankara
| | - E Parlak
- Department of Gastroenterology, Hacettepe University School of Medicine, Ankara
| | - D Oguz
- Department of Gastroenterology, Kırıkkale University School of Medicine, Kırıkkale
| | - E Oztas
- Department of Gastroenterology, Osmangazi University University School of Medicine, Eskisehir
| | - S Kacar
- Department of Gastroenterology, Turkiye Yuksek Ihtısas Hospital, Ankara
| | - F O Onder
- Department of Gastroenterology, Acibadem University School of Medicine, Istanbul
| | - N Sasmaz
- Department of Gastroenterology, Turkiye Yuksek Ihtısas Hospital, Ankara
| | - B Sahin
- Department of Gastroenterology, Turkiye Yuksek Ihtısas Hospital, Ankara
| |
Collapse
|
16
|
Asci A, Cihan A, Sahin B, Deliktas H, Cinar O, Ongun S, Turunc T, Gul U, Kizilkan Y, Gudeloglu A. PO-01-006 Intra-operative audible Micro-Doppler ultrasound for microsurgical varicocelectomy. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.03.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Atalar B, Mustafayev T, Sio T, Sahin B, Gungor G, Aydin G, Yapici B, Ozyar E. P2.16-15 Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Atalar B, Kaytan Sağlam E, Akgün Z, Abacioglu U, Arifoglu A, Sahin B, Ozyar E, Yaprak G, Ozseker Isik N, Caglar Ozkok H, Karaman S, Igdem S, Selek U, Öner Dincbas F, Sengoz M, Başkaya Yucel S, Nur Demiral A, Akyurek S. P2.16-14 Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
19
|
Akdoğan M, Saşmaz N, Kayhan B, Biyikoğlu I, Dişibeyaz S, Sahin B. Extraordinarily Elevated Ca19-9 in Benign Conditions: A Case Report and Review of the Literature. Tumori 2018; 87:337-9. [PMID: 11765186 DOI: 10.1177/030089160108700513] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Carbohydrate antigen CA19-9 is commonly used in the diagnosis of pancreatic and biliary malignancies. However, increases in its level in benign conditions such as acute cholangitis or pancreatitis have also been reported. A 79-year-old woman presented with cholangitis and a pancreatic pseudocyst while showing elevation of CA19-9 up to 35,500 U/mL. The patient was adequately treated and at two months’ follow-up the CA19-9 level had returned to normal.
Collapse
Affiliation(s)
- M Akdoğan
- Department of Gastroenterology, Türkiye Yüksek Ihtisas Hospital, Ankara, Turkey.
| | | | | | | | | | | |
Collapse
|
20
|
Zoto Mustafayev T, Sahin B, Atalar B, Ozyar E. EP-1173: Impact of plasma Epstein-Barr virus-DNA and gross tumor volume on prognosis of nasopharyngeal cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31483-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
21
|
Abstract
Hepatocellular carcinoma has still been one of the cancer with increasing incidence and highest mortality rate in the world. Although many new promising developments have been defined in hepatocarcinogenesis, with a short survival the treatment of patients with advanced hepatocellular carcinoma is an emerging issue. On the recent decade, only one anti-angiogenic agent sorafenib improved overall survival with costing a hardly manageable toxicity. Novel immunotherapeutic agents, especially immune checkpoint inhibitors are on the edge of more effective but less toxic treatments for these patients. In this article the activity of immune checkpoint inhibitors, anti-CTLA-4 and anti-PD1 antibodies for the treatment of patients with advanced hepatocellular cancer will be reviewed.
Collapse
Affiliation(s)
- Berksoy Sahin
- Medical Oncology Department, Cukurova University, Balcali, 01330, Adana, Turkey.
| |
Collapse
|
22
|
Sahin B, Karabulut A, Akbulut M, Kaleli B, Yorukoglu A. Ectopic prostatic tissue in mature cystic teratoma of the ovary, a case report and review of the literature. J OBSTET GYNAECOL 2016; 36:513-4. [PMID: 26757698 DOI: 10.3109/01443615.2015.1103718] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- B Sahin
- a Department of Obstetrics and Gynecology and
| | - A Karabulut
- a Department of Obstetrics and Gynecology and
| | - M Akbulut
- b Department of Pathology , Pamukkale University Medical School , Denizli , Turkey
| | - B Kaleli
- a Department of Obstetrics and Gynecology and
| | - A Yorukoglu
- b Department of Pathology , Pamukkale University Medical School , Denizli , Turkey
| |
Collapse
|
23
|
Ozyar E, Dizman A, Esassolak M, Ikizler A, Yildirim C, Caloglu M, Atalar B, Akman F, Demiroz C, Atasoy B, Can E, Igdem S, Ugurluer G, Kutuk T, Akmansu M, Sahin B. Patterns of Care Study in Turkish Nasopharyngeal Cancer Patients (NAZOTURK): A Turkish Radiation Oncology Association Head and Neck Cancer Working Group Study. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Ercolak V, Sahin B, Gunaldi M, Duman BB, Afsar CU. Efficacy of paclitaxel in the treatment of Kaposi sarcoma. Eur Rev Med Pharmacol Sci 2015; 19:4095-4100. [PMID: 26592833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its systemic treatment, in addition to some chemotherapeutics, taxanes have also been used during the recent years for their anti-angiogenic properties. In this study, we aimed to compare paclitaxel and non-paclitaxel chemotherapeutic regimens in terms of efficacy and side effects. PATIENTS AND METHODS In our center, demographical, clinical and histopathological characteristics of a total of 13 patients diagnosed with Kaposi sarcoma who received therapy were retrospectively recorded based on their medical files RESULTS Among these subjects, 7 have been treated with paclitaxel and 6 with non-paclitaxel therapies. Eleven patients were male. Twelve patients were found to have classical type of Kaposi Sarcoma. The recurrence was observed in 2 patients treated with paclitaxel and in 1 patient treated with non-paclitaxel therapy. No statistically significant difference was found between the therapeutic modality, the stage of the disease and the percentage of the recurrence. Neuropathy developed in 3 patients treated with paclitaxel, whereas there was no neuropathy in the other group. Although the recurrence-free survival was worse in the patients treated with paclitaxel, there was no statistically significant difference. CONCLUSIONS Cytotoxic chemotherapy is effective in treating patients with Kaposi Sarcoma, although it is palliative. Taxanes have demonstrated effectiveness against AIDS-associated Kaposi Sarcoma. The experience suggests that paclitaxel is an effective alternative in the treatment of classical form Kaposi's sarcoma. There was no difference in efficacy between paclitaxel and non-paclitaxel therapies whereas difference in occurrence of neuropathy which is one of the side effects, showed borderline statistical significance.
Collapse
Affiliation(s)
- V Ercolak
- Department of Medical Oncology, Cukurova University Medical Faculty, Adana, Turkey.
| | | | | | | | | |
Collapse
|
25
|
Bilgili M, Simsek E, Sahin B, Yasar A, Ozbek A. Estimation of human heat loss in five Mediterranean regions. Physiol Behav 2015; 149:61-8. [DOI: 10.1016/j.physbeh.2015.05.027] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2014] [Revised: 04/28/2015] [Accepted: 05/24/2015] [Indexed: 11/28/2022]
|
26
|
Damania D, Kung NTM, Jain M, Jain AR, Liew JA, Mangla R, Koch GE, Sahin B, Miranpuri AS, Holmquist TM, Replogle RE, Benesch CG, Kelly AG, Jahromi BS. Factors associated with recurrent stroke and recanalization in patients presenting with isolated symptomatic carotid occlusion. Eur J Neurol 2015; 23:127-32. [PMID: 26332023 PMCID: PMC5049615 DOI: 10.1111/ene.12819] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 06/29/2015] [Indexed: 11/28/2022]
Abstract
Background and purpose Patients with symptomatic internal carotid artery (ICA) occlusion constitute a small proportion of stroke/transient ischaemic attack patients who are at increased risk of early stroke recurrence and poor outcome. The optimal medical treatment for patients with symptomatic ICA occlusion who are ineligible for thrombolysis or thrombectomy is unknown. Methods Consecutive patients presenting at a single center with newly diagnosed symptomatic ICA occlusion (not involving the circle of Willis) were retrospectively reviewed. Those treated with intravenous thrombolysis or intra‐arterial thrombolysis/thrombectomy were excluded. Patients were divided into two groups based on whether they experienced recurrent in‐hospital stroke. Results The selected study population (n = 33) represented a small (20.4%) proportion of all newly symptomatic carotid occlusions, who nevertheless had an elevated risk of recurrent stroke during admission (24.2%). Of the variables examined (age, gender, admission National Institutes of Health Stroke Scale score, vascular risk factors, atrial fibrillation, prior stroke/transient ischaemic attack and anticoagulation within 48 h of presentation), only anticoagulation was significantly associated with a lower risk of in‐hospital recurrent stroke. Anticoagulated patients showed a decreased incidence of stroke recurrence within the first week (6.7% vs. 38.9%, P = 0.032) and fewer strokes or deaths at 1 month (13.3% vs. 47.1%, P = 0.040). Hemorrhagic transformation was not observed in any patient. On follow‐up imaging, ICA recanalization was significantly more frequent in anticoagulated patients (46.2% vs. 9.1%, P = 0.047). Conclusion Patients with newly diagnosed symptomatic ICA occlusion (not involving the circle of Willis) represent a small but high risk subgroup of patients with carotid occlusion. Early anticoagulation was associated with fewer recurrent strokes and increased ICA recanalization. Larger scale prospective studies may be justified.
Collapse
Affiliation(s)
- D Damania
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - N T-M Kung
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - M Jain
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - A R Jain
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - J A Liew
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - R Mangla
- Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA
| | - G E Koch
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - B Sahin
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - A S Miranpuri
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - T M Holmquist
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - R E Replogle
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| | - C G Benesch
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - A G Kelly
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - B S Jahromi
- Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA
| |
Collapse
|
27
|
Usul Afsar C, Sahin B, Gunaldi M, Kılıc Bagir E, Gumurdulu D, Burgut R, Erkisi M, Kara IO, Paydas S, Karaca F, Ercolak V. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung. Int J Clin Exp Pathol 2015; 8:9760-9771. [PMID: 26617686 PMCID: PMC4637771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/18/2015] [Accepted: 08/25/2015] [Indexed: 06/05/2023]
Abstract
AIM Non-small cell lung carcinoma is the leading cause of cancer related to death in the world. Squamous cell lung carcinoma (SqCLC) is the second most frequent histological subtype of lung carcinomas. Recently, growth factors, growth factor receptors, and signal transduction system-related gene amplifications and mutations are extensively under investigation to estimate the prognosis and to develop individualized therapies in SqCLC. In this study, besides the signal transduction molecule phosphatidyl inositol-3-phosphate kinase (IP3K) p110α, we explored the expressions of fibroblast growth factor 2 (FGF2) and receptor-1 (FGFR1) in tumor tissue and also their clinical and prognostic significance in patients with early/advanced SqCLC. MATERIALS AND METHODS From 2005 to 2013, 129 patients (23 early, 106 advanced disease) with a histopathological SqCLC diagnosis were selected from the hospital files of Cukurova University Medical Faculty for this study. Two independent pathologists evaluated FGFR1, FGF2, and PI3K (p110α) expressions in both tumor and stromal tissues from 99 of the patients with sufficient tissue samples, using immunohistochemistry. Considering survival analysis separately for patients with both early and advanced stage diseases, the relationship between the clinical features of the patients and expressions were evaluated by univariate and multivariate analyses. RESULTS FGFR1 expression was found to be low in 59 (60%) patients and high in 40 (40%) patients. For FGF2; 12 (12%) patients had high, 87 (88%) patients had low expression and for IP3K; 31 (32%) patients had high and 66 (68%) patients had low expressions. In univariate analysis, overall survival (OS) was significantly associated with stage of the disease and the performance status of the patient (P<0.0001 and P<0.001). There was no significant difference in OS of the patients with either low or high expressions of FGFR1, FGF2, and IP3K. When the patients with early or advanced stage disease were separately taken into consideration, the relationship did not differ, either. Any of FGFR1, FGF2 or IP3K expressions was not found predictive for the treatment of early or advanced staged patients. On the other hand, the expressions of both FGFR1 and FGF2 were significantly different with respect to smoking, scar of tuberculosis and scar of radiotherapy (P=0.002; P=0.06 and P=0.05, respectively). DISCUSSION There has not been identified an effective individualized treatment for SqCLC yet. Therefore, in order to be able to develop such a treatment in the future, it is essential to identify the genetic abnormalities that are responsible for the biological behaviors and carcinogenesis of SqCLC. Although we could not show the prognostic and predictive significance of FGFR1, FGF2 and IP3K expressions in SqCLC, we determined the expression rates of FGFR1, FGF2 and IP3K as a reference for Turkish patients. In conclusion, we want to put some emphasis on the fact that, pulmonary fibrosis which is a late complication of radiotherapy at stage III disease, and the scar of tuberculosis could be associated with FGFR1 and FGF2 expressions.
Collapse
Affiliation(s)
- Cigdem Usul Afsar
- Department of Medical Oncology, Istanbul Training and Research Hospital Istanbul, Turkey
| | - Berksoy Sahin
- Department of Medical Oncology, Cukurova University Medical Faculty Adana, Turkey
| | - Meral Gunaldi
- Department of Medical Oncology, Bakirkoy Sadi Konuk Research and Treatment Hospital Istanbul, Turkey
| | - Emine Kılıc Bagir
- Department of Pathology, Cukurova University Medical Faculty Adana, Turkey
| | - Derya Gumurdulu
- Department of Pathology, Cukurova University Medical Faculty Adana, Turkey
| | - Refik Burgut
- Department of Bioistatistics, Cukurova University Medical Faculty Adana, Turkey
| | - Melek Erkisi
- Department of Medical Oncology, Cukurova University Medical Faculty Adana, Turkey
| | - Ismail Oguz Kara
- Department of Medical Oncology, Cukurova University Medical Faculty Adana, Turkey
| | - Semra Paydas
- Department of Medical Oncology, Cukurova University Medical Faculty Adana, Turkey
| | - Feryal Karaca
- Department of Radiation Oncology, Adana Numune Research and Education Hospital Adana, Turkey
| | - Vehbi Ercolak
- Department of Medical Oncology, Mersin State Hospital Mersin, Turkey
| |
Collapse
|
28
|
Afsar CU, Gunaldi M, Kum P, Sahin B, Erkisi M, Kara IO, Paydas S, Duman BB, Ercolak V, Karaca F, Uyeturk U, Guner SI. Pancreatic carcinoma, thrombosis and mean platelet volume: single center experience from the southeast region of Turkey. Asian Pac J Cancer Prev 2015; 15:9143-6. [PMID: 25422192 DOI: 10.7314/apjcp.2014.15.21.9143] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND The aim of this study was to investigate the general characteristics of patients with deep vein thrombosis (DVT) and pancreatic cancer as well as evaluate the relationship between mean platelet volume (MPV), DVT and survival. MATERIALS AND METHODS Seventy-seven patients with pancreatic cancer, who were admitted to Cukurova University Medical Faculty, Department of Medical Oncology, were enrolled in the study RESULTS The mean age was 59±20. Forty-nine (63.6%) were men and 28 women (36.4%) . Sixty-eight (88.3%) patients had adenocarcinoma and 9 (11.7%) had a malignant epithelial tumor. Thirty-six (46.7%) had liver metastasis at diagnosis. Twenty-six (33.8%) patients were alive, 20 (26%) were dead and in 31 (40.2%) the status was unknown. Only 14 (18.1%) patients had DVT. In 42 (54.5%) patients MPV values were normal, in 28 (36.4%) patients they were above normal, and in 7 (9.1%) patients they were below normal. There was no statistically significant difference between gender, tumour localization, chemotherapy and survival rates (p:0.56, p:0.11, p:0.21). There was no significant difference between DVT, gender, localisation, histological subtype, the presence of metastasis, stage and if the patient had been treated with chemotherapy (p:0.5, p:0.6, p:0.2, p:0.32, p:0.1, p:0.84). There was also no significant difference between MPV and DVT (p:0.57) but there was a significant difference between liver metastasis and DVT (p:0.02). Age, stage, the presence of metastasis and DVT were prognostic in pancreatic cancer patients. CONCLUSIONS Cases of pancreatic cancer with liver metastasis should be studied more carefully as thrombosis is more common in these patients.
Collapse
Affiliation(s)
- Cigdem Usul Afsar
- Department of Medical Oncology, Bahcelievler Medical Park Hospital, Istanbul, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Ozgen M, Akyol L, Sahin B, Sayarlıoglu M. AB0036 Comparison of Tuberculin Skin Test and T-Spot.TB Test in Patients with Receiving Corticosteroid or Immunosuppressive Treatments. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Usul Afsar C, Gunaldi M, Karaca F, Kara IO, Sahin B, Duman BB, Erkisi M, Paydas S. The effect of platinum and docetaxel based chemoradiotherapy on survival in locally advanced unresectable non-small cell lung cancer patients. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e18538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Meral Gunaldi
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital Department of Medical Oncology, Istanbul, Turkey
| | - Feryal Karaca
- Van Education and Research Hospital, Department of Radiation Oncology, Van, Turkey
| | | | - Berksoy Sahin
- Cukurova University Department of Medical Oncology, Adana, Turkey
| | | | - Melek Erkisi
- Çukurova University Medical School, Department of Medical Oncology, Adana, Turkey
| | - Semra Paydas
- Cukurova University Faculty of Medicine, Department of Oncology, Adana, Turkey
| |
Collapse
|
31
|
Günaldi M, Afsar CU, Duman BB, Kara IO, Tatli U, Sahin B. Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws. Oncol Lett 2015; 10:439-442. [PMID: 26171047 DOI: 10.3892/ol.2015.3156] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 03/24/2015] [Indexed: 11/06/2022] Open
Abstract
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.
Collapse
Affiliation(s)
- Meral Günaldi
- Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - Cigdem Usul Afsar
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| | - Berna Bozkurt Duman
- Department of Medical Oncology, Adana Research and Training Hospital, Adana, Adana, Turkey
| | - Ismail Oguz Kara
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| | - Ufuk Tatli
- Faculty of Dentistry, Cukurova University, Adana, Adana, Turkey
| | - Berksoy Sahin
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| |
Collapse
|
32
|
Gunaldi M, Duman BB, Afsar CU, Paydas S, Erkisi M, Kara IO, Sahin B. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. J Oncol Pharm Pract 2015; 22:242-7. [PMID: 25567518 DOI: 10.1177/1078155214567162] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic. MATERIALS AND METHODS The study was made up of 111 women with human epidermal growth factor receptor 2-overexpressing breast cancer who received trastuzumab in the Medical Oncology Department, between 2010 and 2013. RESULTS A > 10% reduction of the baseline fraction of the left ventricular ejection fraction was observed in 18 (16.21%) women. Two individuals (1.8%) suffered from symptomatic heart failure, seven women showed cardiac symptoms and nine women showed asymptomatic decline of left ventricular ejection fraction. Risk factors for cardiotoxicity in the group included: postmenopausal status (p = 0.01), hypertension (p = 0.002), obesity (p = 0.0001), previously diagnosed coronary artery disease (p = 0.0001) and smoking (p = 0.03). CONCLUSION The aforementioned factors pose a risk for cardiotoxicity. We found postmenopausal status, hypertension, obesity, previous coronary artery disease and smoking to be associated with an increased risk of cardiac dysfunction in women using trastuzumab. While administering trastuzumab to women who have these conditions, one must be aware of the risk of cardiotoxicity of trastuzumab.
Collapse
Affiliation(s)
- Meral Gunaldi
- Department of Medical Oncology, Bakirkoy Research and Training Hospital, Istanbul, Turkey
| | - Berna Bozkurt Duman
- Department of Medical Oncology, Adana Research and Training Hospital, Istanbul, Turkey
| | - Cigdem Usul Afsar
- Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey
| | - Semra Paydas
- Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey
| | - Melek Erkisi
- Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey
| | - I Oguz Kara
- Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey
| | - Berksoy Sahin
- Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey
| |
Collapse
|
33
|
Günaldı M, Erkisi M, Afşar CU, Erçolak V, Paydas S, Kara IO, Sahin B, Gulec UK, Secilmis A. Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment. Pharmacology 2014; 94:183-9. [PMID: 25378122 DOI: 10.1159/000363304] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 04/29/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND Several previous studies have examined the effect of CYP2D6 gene polymorphism on the efficacy and metabolism of tamoxifen (Tamoxifen Teva, Nolvadex) in the treatment of breast cancer. In the present study, the metabolic profiles associated with various CYP2D6 genotypes were evaluated. METHOD In the present study 92 Turkish breast cancer patients with early-stage hormone receptor-positive tumors treated with adjuvant tamoxifen (20 mg) were evaluated for CYP2D6 genotype and metabolic profiles. Known side effects of tamoxifen treatment, including endometrial thickening, changes in serum lipid levels and bone density, and hepatosteatosis, were evaluated according to the CYP2D6 polymorphism. RESULT The distribution of metabolic characteristics in the Turkish population was as follows: 77.1% normal metabolism, 11.5% intermediate metabolism, 5.2% ultrarapid metabolism, and 2.1% poor metabolism. The CYP2D6 genotypes associated with rapid metabolism were CYP2D6 3X*1/*1 duplication (DUP) and CYP2D6 2X*1/*2, while poor metabolism was associated with the genotypes CYP2D6 *3/*4 and CYP2D6 *6/*6. There was no statistically significant relationship between metabolic characteristics and bone density or hepatosteatosis. A statistically significant difference in total cholesterol and triglycerides was detected in lipid profile analysis (p = 0.003, p = 0.02). Assessment of endometrial thickness revealed a significant association of hyperplasia and poor metabolism, and an association between atrophy and ultrarapid metabolism (p = 0.01). CONCLUSION Significant development of endometrial hyperplasia was identified among individuals with poor tamoxifen metabolism. As a result, tamoxifen may be a significant predictor of endometrial thickening among individuals with poor metabolic characteristics.
Collapse
Affiliation(s)
- Meral Günaldı
- Department of Medical Oncology, Çukurova University Medical School, Adana, Turkey
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Sahin B. SP-045 HOW I MANAGE INDOLENT NON-HOGDKIN LYMPHOMA? Leuk Res 2014. [DOI: 10.1016/s0145-2126(14)70041-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Usul Afsar C, Sahin B, Gumurdulu D, Kılıc Bagır E, Burgut R, Erkisi M, Kara O, Gunaldi M, Ercolak V. The Evaluation of Fibroblast Growth Factor Receptor 1 (Fgfr1), Fibroblast Growth Factor 2 (Fgf2), Phosphatidylinositol 3 Phosphate Kinase (Ip3K) Expression and Their Clinical, Prognostic Significance in Early and Advanced Stage of Squamous Cell Carcinoma of the Lung. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Akın MS, Duman BB, Sahin B. Göğüs Kanserinde Flow Sitometri ile Tespit Edilenen Kemik İliği Mikrometastazının Kemik, Kemik İliği, ve Akciğer Makrometastazları ile İlişkilidir. Cukurova Medical Journal 2014. [DOI: 10.17826/cutf.38648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Gunaldi M, Erkisi M, Usul Afsar C, Ercolak V, Paydas S, Kara IO, Sahin B, Gulec U, Secilmis A. The evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisims in Turkish breast cancer patients receiving tamoxifen treatment. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e11559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Meral Gunaldi
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital Department of Medical Oncology, Istanbul, Turkey
| | - Melek Erkisi
- Çukurova University Medical School, Department of Medical Oncology, Adana, Turkey
| | | | - Vehbi Ercolak
- Çukurova University Medical School, Department of Medical Oncology, Adana, Turkey
| | - Semra Paydas
- Cukurova University Faculty of Medicine, Adana, Turkey
| | - Ismail Oguz Kara
- Cukurova University Department of Medical Oncology, Adana, Turkey
| | - Berksoy Sahin
- Cukurova University Medical Faculty Department of Medical Oncology, Adana, Turkey
| | - Umran Gulec
- Çukurova University Medical School, Department of Gynecology, Adana, Turkey
| | - Ata Secilmis
- Çukurova University Medical School, Department of Pharmacology, Adana, Turkey
| |
Collapse
|
38
|
Onuk B, Kabak M, Sahin B, Ince NG, Selcuk MB. New method for estimating the volume and volume fractions of the nasal structures in the goose (Anser anser domesticus) using computed tomography images. Br Poult Sci 2014; 54:441-6. [PMID: 23906217 DOI: 10.1080/00071668.2013.806980] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. The conchae within the nasal cavity of poultry are important for water and energy conservation, but have not been experimentally evaluated. The aim of the present study was to determine the accuracy of volume and volume fraction estimates of the conchae, nasal septum and nasal cavity. 2. The nasal cavities of 7 adult goose heads were scanned using computed tomography (CT), with images sampled randomly at a 1/5 sampling fraction. Physical sections were obtained from the same samples, using an electric saw that had an adjustable section range, and provided 14 to 15 sections with a thickness of 2.5 mm. The section surface areas of the nasal cavity, nasal septum and conchae were estimated using the Cavalieri principle. Results obtained using the CT and physical section images were compared. Volumes and volume fractions obtained from the physical sections were accepted as the gold standard and differences in the CT images were determined. 3. Multiplication of the data obtained on the CT images with the deviation percentage of the physical sections produced normalised values. No differences were observed between the gold standard data and the CT images. While it was possible to normalise the obtained data using the gold standard values, the raw data could also be used for comparative studies because the deviations from normal would be similar for all groups. 4. Our study showed that the nasal structures could be estimated in vivo using CT images.
Collapse
Affiliation(s)
- B Onuk
- Department of Anatomy, Faculty of Veterinary Medicine, Ondokuz Mayıs University, Samsun, Turkey.
| | | | | | | | | |
Collapse
|
39
|
Turk F, Atinkaya C, Yuncu G, Ekinci Y, Sahin B, Atalay H, Aybek H, Bir F. F-034THE COMPARISON OF TRACHEOTOMY AND TRANSLARYNGEAL INTUBATION REGARDING FREE RADICAL FORMATION AND EFFECT ON THE LUNG IN RATS. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
|
41
|
Ozgoren M, Dogan S, Okbaz A, Aksoy MH, Sahin B, Akıllı H. Comparison of Flow Characteristics of Different Sphere Geometries Under the Free Surface Effect. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20134501022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
|
43
|
Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J BUON 2013; 18:44-50. [PMID: 23613387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
PURPOSE Mutations that activate the PIK3CA oncogene and inhibit the tumor suppressor gene PTEN action are commonly found in breast tumors. Akt is a key activator of cell survival. p53 is frequently found mutated in human tumors, and mutant p53 protein actively contributes to tumorigenesis. In selected cases of breast cancer, trastuzumab (TZMB) is incorporated in the primary treatment in the adjuvant and metastatic settings. Many studies have reported that selected patients are resistant to TZMB due to the presence of p95 HER2 fragments. To address this, we analysed PTEN, Akt, MAPK, p53 and p95 expression in breast cancer patients treated with TZMB. METHODS Out of 90 patients histologically diagnosed with breast cancer between 2004 and 2011, analysed were 25 patients with HER2 positive, and estrogen (ER) and progesterone receptors (PR) negative, metastatic or locally advanced disease. All 25 patients were treated with TZMB and resistance to TZMB was assessed. All patients were on anthracycline-and taxane-containing regimens. Tissue samples were obtained from paraffin blocks and evaluated immunohistochemically for PTEN, Akt, MAPK, p53, and p95 expression. RESULTS TZMB resistance was detected in 5 (20%) patients. Akt expression was positive in 2 patients (8%) and MAPK, p95, and p53 expression was positive in 1 patient (4%); PTEN expression was negative in 3 patients (12%). No significant differences were found between TZMB resistance and PTEN, Akt, MAPK, p53, and p95 expression. Subgroup analysis was carried out in the neoadjuvant treatment group. Complete pathologic response was detected in 3 patients (21.4%). Statistically significant differences were not found between the complete response rate and PTEN, Akt, MAPK, and p95 expression. There was a statistically significant correlation between p53 expression and complete pathologic response (p=0.02). CONCLUSION No statistically significant correlation between TZMB resistance and the expression of these biomarkers was noted. In patients with HER2-positive breast cancer that were treated with 4 dose-dense sequential cycles of doxorubicin and cyclophosphamide, followed by TZMB and paclitaxel combination therapy in the neodjuvant setting, p53 expression could predict complete response to chemotherapy.
Collapse
Affiliation(s)
- B B Duman
- Department of Medical Oncology, Cukurova University Medical Faculty, Adana, Turkey.
| | | | | | | | | |
Collapse
|
44
|
Duman BB, Gunaldi M, Ercolak V, Afsar CU, Sahin B, Erkisi IMK, Kara O, Paydas S, Gönlüsen G, Sertdemir Y. Retrospective analysis of 498 primary soft tissue sarcomas in a single Turkish centre. Asian Pac J Cancer Prev 2012; 13:4125-8. [PMID: 23098528 DOI: 10.7314/apjcp.2012.13.8.4125] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Soft tissue sarcomas (STS) must be managed with a team involving pathologists, radiologists, surgeons, radiation therapists and medical oncologists. Treatment modalities and demographic characteristics of Turkish STS were analysed in the current study. MATERIAL-METHODS Primary adult STS followed between 1999- 2010 in Cukurova University Medical Faculty Department of Medical Oncology were analyzed retrospectively. RESULTS Of the total of 498 patients, 238 were male and 260 female. The most seen adult sarcomas were leomyosarcoma (23%). Localization of disease was upper extremity (8.8%), lower extremity (24.7%), head-neck 8.2%, thoracic 8%, retroperitoneal 5.6%, uterine 12.4%, abdominal 10%, pelvic region 3.6 and other regions 10%. Some 13.1% were early stage, 10.2% locally advanced, 8.2% metastatic and 12.2% recurrent disease. Patients were treated with neoadjuvant/adjuvant (12%) or palliative chemotherapy (7.2%) and 11.4% patients did not receive chemotherapy. Surgery was performed as radical or conservative. The most preferred regimen was MAID combination chemotherapy in the rate of 17.6%. The most common metastatic site was lung (18.1%). The overall survival was 45 months (95%CI 30-59), 36 months in men and 55 months in women, with no statistically significant difference (p=0.5). The survival rates were not different between the group of adjuvant and palliative chemotherapy (respectively 28 versus 18 months) (p=0.06), but radical surgery at 37 months was better than 22 months for conservative surgery (p=0.0001). No differences were evident for localization (p=0.152). Locally advanced group had higher overall survival rates (72 months) than other stages (p=0.0001). CONCLUSION STS can be treated successfully with surgery, chemotherapy and radiotherapy. The survival rates of Turkish people were higher in locally advanced group; these results show the importance of multimodality treatment approach and radical surgery.
Collapse
|
45
|
Ulker M, Duman B, Sahin B, Gumurdulu D. Ercc1 Expression as Predictive Biomarker for Platinum Containing Chemotherapy Regimens in Ovarian Carcinoma. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33547-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
Parlak E, Köksal AS, Onder FO, Dişibeyaz S, Tayfur O, Ciçek B, Saşmaz N, Sahin B. ERCP in patients with Jaboulay pyloroplasty. Acta Gastroenterol Belg 2012; 75:373-374. [PMID: 23082716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
47
|
Duman BB, Afsar CU, Gunaldi M, Sahin B, Kara IO, Erkisi M, Ercolak V. Retrospective Analysis of Neoadjuvant Chemotherapy for Breast Cancer in Turkish Patients. Asian Pac J Cancer Prev 2012. [DOI: 10.7314/apjcp.2012.13.8.4119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Sisman H, Sahin B, Duman BB, Tanriverdi G. Nurse-assisted education and exercise decrease the prevalence and morbidity of lymphedema following breast cancer surgery. J BUON 2012; 17:565-569. [PMID: 23033300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
PURPOSE To evaluate an educational and exercise program for the prevention and progression of post-mastectomy lymphedema of the arm and shoulder. METHODS Fifty-five patients who had undergone mastectomy and axillary lymph node dissection between June 2009 and January 2010 were included in this study. The patients were informed by a trainer nurse about the precautions they should take to prevent the development of lymphedema. The patients were also trained for the appropriate exercises and were given written educational material prepared by the investigators. RESULTS Among the participants, 96.4% underwent modified radical mastectomy (MRM) and 3.6% breast-conserving (BCS) surgery. The mean postoperative follow-up period was 9.87 ± 17.55 months. The degree of lymphedema was found lower, even within 6 months, in the patients that exercised as compared to the patients that did not (p<0.05). CONCLUSIONS The results indicate that the risk of development and progression of mastectomy-related lymphedema was reduced with education and exercise provided by trained nurses at an early stage.
Collapse
Affiliation(s)
- H Sisman
- Department of Nursing, Cukurova University Medical Faculty, Balcali, Adana, Turkey
| | | | | | | |
Collapse
|
49
|
Duman BB, Sahin B, Ergin M, Zorludemir S, Acikalin A. Expression of PTEN, Akt, MAPK, p53, p95 for predicting trastuzumab resistance in breast cancer. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e11088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11088 Background: The activation of the oncogene PIK3CA and the loss of the tumor suppressor gene PTEN are mutations commonly found in breast tumors. AKT is a key activator of cell survival mechanisms. Mutant p53 proteins can actively contribute to tumorigenesis. Trastuzumab in particular are the primary treatment in the adjuvant and recurrent settings for breast cancer. Many studies reported that selected patients may present with resistance to trastuzumab due to the presence of p95 HER2 fragments. To address this challenge,we analyzied PTEN, Akt, MAPK, p53, p95expressions in breast cancer treated with trastuzumab therapy. . Methods: Ninety patients were assessed for this study and in the guidance of inclusion and exclusion criteria 25 patients were enrolled to the study. HER2 positivite, metastatic or locally advanced patients were enrolled to the study.. All of the patients that included to the study were treated with trastuzumab. Trastusumab resistance was assessed. Antracylin and taxane containing regimens were given to all patients. Gemcitabine, cisplatine capectabine, navelbine containing regimens were given on second and third line treatment choices. Tissue samples were obtained from parafine blocks and evaluated for PTEN, Akt, mapk, p53, p95 expression with immunohistochemical method. Results: The median age was 54±12. PTEN, Akt, MAPK, p53, p95 expressions were found in different levels on tumor tissue samples. Trastuzumab resistance were detected in 5 (20%) patients. Akt expression was positive in 2(8%) patients, MAPK expression was positive in 1 (4%) patient, p95 expression was positive in 1 (4%) patient, p53 expression was positive in 1 (4%) patient, PTEN expression was negative 3 (12%). Statistically significant difference was not found between trastuzumab resistance and PTEN, Akt, MAPK, p53, p95 expressions (respectively p:0,11, 0,79, 0,95, 0,88, 0,74). Conclusions: PTEN, Akt, MAPK, p53, p95expressions were assessed on HER2 positive breast cancers for predicting trastuzumab resistance. There was no statistically significant correlations between trastuzumab resistance and the expressions of these biomarkers. This study is ongoing, this is the preliminary results of this study.
Collapse
Affiliation(s)
| | - Berksoy Sahin
- Cukurova University Medical Faculty Department of Medical Oncology, Adana, Turkey
| | - Melek Ergin
- Cukurova University Medical Faculty Department of Pathology, Adana, Turkey
| | - Suzan Zorludemir
- Cukurova University Medical Faculty Department of Pathology, Adana, Turkey
| | - Arbil Acikalin
- Cukurova University Medical Faculty Department of Pathology, Adana, Turkey
| |
Collapse
|
50
|
Emirzeoglu M, Sahin B, Celebi M, Uzun A, Bilgic S, Tontus HO. Estimation of nasal cavity and conchae volumes by stereological method. Folia Morphol (Warsz) 2012; 71:105-108. [PMID: 22648589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Studies evaluating the mean volumes of nasal cavity and concha are very rare. Since there is little date on the mentioned topic, we aimed to carry out the presented study to obtain a volumetric index showing the relation between the nasal cavity and concha. MATERIAL AND METHODS The volumes of the nasal cavity and concha were measured in 30 males and 30 females (18-40 years old) on computed tomography images using stereological methods. RESULTS The mean volumes of nasal cavity, concha nasalis media, and concha nasalis inferior were 5.95 ± 0.10 cm(3), 0.56 ± 0.22 cm(3), and 1.45 ± 0.68 cm(3); 7.01 ± 0.18 cm(3), 0.67 ± 0.31 cm(3) and 1.59 ± 0.98 cm(3) in females and males, respectively. There were statistically significant differences in the volume of the nasal cavity and concha nasalis media (p 〈 0.05) between males and females, except for concha nasalis inferior (p 〉 0.05). CONCLUSIONS Our results could provide volumetric indexes for the nasal cavity and concha, which could help the physician to manage surgical procedures related to the nasal cavity and concha.
Collapse
Affiliation(s)
- M Emirzeoglu
- Anatomy Department, Ondokuz Mayis University, Samsun, Turkey.
| | | | | | | | | | | |
Collapse
|